Gapping up
In reaction to strong earnings/guidance:
- LCI +17.1%, PSDO +13.9%, IRBT +12.4%, CMG +10.2%, MTCH +10%, HEAR +9.2%, CAH +7%, ZNGA +6.7%, HBI +6%, MC +5.8%, SRCI +5.6%, NOV +4.6%, MAS +3.5%, FTNT +3.4%, VSTO +2.6%, GPRO +2.5%, HQY +2.5%, UHAL +2.4%, DHT +2.2%, ANDX +2.2%, FORM +2.1%, ORLY +2.1%, AHH +1.9%, SNN +1.7%, ENSG +1.3%, CCR +1.1%, MPC +0.8%, TMUS +0.8%
M&A news:
- STI +9.1% (BB&T Corp and SunTrust to combine in all-stock merger of equals valued at approximately $66 bln), BBT +4.8%
Other news:
- IAC +6.9% (following MTCH results)
- SRPT +6.7% (n response to Solid Biosciences (SLDB -64%) DMD setback)
- PRTK +4.2% (publication of results from the OPTIC and OASIS-1 Phase 3 clinical studies of NUZYRA)
- ARRY +2.4% (after seeing notable option activity in late trade - coinciding with strength in the underlying stock)
- DEO +2% (approves increase to the share buyback programme -- F19 Programme will now return up to £3.0 billion to shareholders)
- AAP +1.8% (following ORLY results)
- CNC +1.3% (rebounding after CEO appearance on CNBC)
Analyst comments:
- MGNX +4.5% (upgraded to Buy from Sell at Citigroup)
- IOVA +4.3% (initiated with Outperform at Robert W Baird)
- HQY +4% (upgraded to Buy from Hold at SunTrust)
- GES +1.6% (upgraded to Buy from Hold at Jefferies)
- PCAR +1.1% (upgraded to Outperform from Neutral at Robert W. Baird)
- CTSH +0.8% ( upgraded to Outperform from Market Perform at BMO Capital Markets)
- WBC +0.8% (upgraded to Outperform from Neutral at Robert W. Baird)
